Caring for Patients with IBD in an Evolving Treatment Landscape: Optimizing Outcomes and Minimizing ComplicationsPremiere Date: Monday, December 23, 2019
This activity offers CE credit for:%>
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- ABIM (MOC)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, December 31, 2020
Note: Credit Is No Longer Available
|David T. Rubin, MD, FACG, AGAF, FACP, FASGE, FRCP (Edinburgh) (Moderator)
Joseph B. Kirsner Professor of Medicine
Chief, Section of Gastroenterology, Hepatology and Nutrition
Director, Inflammatory Bowel Disease Center
University of Chicago Medicine
|Jami Kinnucan, MD
Assistant Professor of Medicine Assistant Program
Director, Gastroenterology Fellowship
Program Director, IBD Fellowship Education
Division of Gastroenterology and Hepatology
Department of Internal Medicine
Michigan Medicine, University of Michigan
Ann Arbor, MI
|Gil Y. Melmed, MD, MS
Professor of Medicine
Director of IBD Clinical Research
Associate Director of Gastroenterology and Hepatology
Los Angeles, CA
With the introduction of new treatments, treatment targets, and updated guidelines, the management of inflammatory bowel disease (IBD) is constantly evolving yet remains suboptimal. Despite being treated, many patients with IBD are not in remission or lose response to their current therapy over time. Personalized approaches are necessary, as they optimize response and integration of new drug classes, which are both important to the treatment paradigm.
Janus kinase (JAK) inhibitors are one of the new treatment options for patients with IBD, and many patients prefer them over infusions and/or injections, as they are administered orally. Being rapid-acting and effective, they, along with appropriate monitoring, can reduce the risk of common complications like anemia, which is frequently overlooked in patients with IBD.
This CME Outfitters webcast features a panel of expert faculty utilizing an interactive, animated 3-D model to enhance the discussion on the mechanism of action (MOA) of JAK inhibitors, the pathophysiology of IBD, and the development of anemia, to assist HCPs in selecting the appropriate therapy for patients with IBD.
At the end of this CE activity, participants should be able to:
- Evaluate JAK inhibitors for IBD in terms of MOA, efficacy, and safety.
- Monitor patients with IBD for iron deficiency and anemia.
- Select treatment for patients with IBD, taking into account disease history, disease severity, and patient preference.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Evaluate JAK inhibitors for IBD in terms of MOA, efficacy, and safety.
- Explain how to monitor patients with IBD for iron deficiency and anemia.
- Identify treatments for patients with IBD, taking into account disease history, disease severity, and patient preference.
Supported by an educational grant from Pfizer Inc.
Gastroenterologists, gastroenterology fellows, nurse practitioners, physician assistants, nurses, and pharmacists.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Rubin reports that he receives grants from AbbVie Inc.; Genentech, Inc./Roche; Janssen Pharmaceuticals, Inc.; Prometheus Laboratories Inc.; Shire; and Takeda Pharmaceuticals U.S.A., Inc. He is a consultant for AbbVie Inc.; AbGenomics; Allergan; Arena Pharmaceuticals, Inc.; Biomica; Bristol-Myers Squibb Company; Dizal Pharmaceutical; Eli Lilly and Company; Ferring Pharmaceuticals Inc.; Genentech, Inc./Roche; Janssen Pharmaceuticals, Inc.; Medtronic; Merck & Co., Inc.; Napo Pharmaceuticals, Inc.; Pfizer Inc.; Shire; Takeda Pharmaceuticals U.S.A., Inc.; and TARGET PharmaSolutions, Inc. He receives other financial or material support as a member of the Board of Trustees for the American College of Gastroenterology; as Co-Founder, CFO of Cornerstones Health, Inc. (non-profit); and as Co-Founder of GoDuRn, LLC.
Tony Graham, MD (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Olga Askinazi, PhD (planning committee) has no disclosures to report.
Susan Perry (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).